Q-omics provides the consensus-scored ATP6V1FNB profile across patient tissues and cancer cell-line models. ATP6V1FNB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP6V1FNB is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ATP6V1FNB RNA expression shows 18,301 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where ATP6V1FNB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP6V1FNB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP6V1FNB survival associations across molecular data types. ATP6V1FNB RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP6V1FNB RNA expression–survival associations across cancer types. High ATP6V1FNB expression shows unfavorable associations in KIRC, ACC, UCEC, LUAD and LIHC, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP6V1FNB RNA expression.
This table summarizes ATP6V1FNB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ATP6V1FNB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP6V1FNB shows lower tumor expression in KICH and higher tumor expression in THCA, COAD, KIRP, LIHC and LUAD. The THCA box plot shows higher ATP6V1FNB RNA expression in tumor versus normal tissue (log2 FC = +1.692, t-test p < 0.001).
This table shows molecular features associated with ATP6V1FNB in patient tissues and cancer cell lines. In patient samples, ATP6V1FNB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP6V1FNB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT.
